<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

The Benefits of Cell Line-Derived Xenograft Models for Preclinical Oncology Screening

Sep 14, 2023 4:30:46 PM / by Champions Oncology posted in Translational Oncology


Preclinical oncology research is a critical component in the development of new cancer therapeutics, and it is essential that drug candidates are carefully screened before they are tested in human clinical trials. One valuable tool in preclinical oncology research is the use of cell line-derived xenograft (CDX) models. In this blog post, we will explore the benefits of CDX models for preclinical oncology screening and how they can be used to improve our understanding of cancer and the development of new treatments.

Read More →